Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 3
2018 3
2019 4
2020 3
2021 4
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Recombinant Newcastle disease viruses expressing immunological checkpoint inhibitors induce a pro-inflammatory state and enhance tumor-specific immune responses in two murine models of cancer.
Santry LA, van Vloten JP, AuYeung AWK, Mould RC, Yates JGE, McAusland TM, Petrik JJ, Major PP, Bridle BW, Wootton SK. Santry LA, et al. Among authors: van vloten jp. Front Microbiol. 2024 Jan 24;15:1325558. doi: 10.3389/fmicb.2024.1325558. eCollection 2024. Front Microbiol. 2024. PMID: 38328418 Free PMC article.
Kinetic analysis of oncolytic OrfV-induced innate and adaptive immune responses in a murine model of late-stage ovarian cancer.
Minott JA, van Vloten JP, Yates JGE, Santry LA, Matuszewska K, Pereira M, Goens MM, Viloria-Petit AM, Wood GA, Karimi K, Petrik JJ, Bridle BW, Wootton SK. Minott JA, et al. Among authors: van vloten jp. Mol Ther Oncolytics. 2023 Nov 10;31:100748. doi: 10.1016/j.omto.2023.100748. eCollection 2023 Dec 19. Mol Ther Oncolytics. 2023. PMID: 38075247 Free PMC article.
A promoterless AAV6.2FF-based lung gene editing platform for the correction of surfactant protein B deficiency.
Thomas SP, Domm JM, van Vloten JP, Xu L, Vadivel A, Yates JGE, Pei Y, Ingrao J, van Lieshout LP, Jackson SR, Minott JA, Achuthan A, Mehrani Y, McAusland TM, Zhang W, Karimi K, Vaughan AE, de Jong J, Kang MH, Thebaud B, Wootton SK. Thomas SP, et al. Among authors: van vloten jp. Mol Ther. 2023 Dec 6;31(12):3457-3477. doi: 10.1016/j.ymthe.2023.10.002. Epub 2023 Oct 7. Mol Ther. 2023. PMID: 37805711 Free article.
Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer.
van Vloten JP, Matuszewska K, Minow MAA, Minott JA, Santry LA, Pereira M, Stegelmeier AA, McAusland TM, Klafuric EM, Karimi K, Colasanti J, McFadden DG, Petrik JJ, Bridle BW, Wootton SK. van Vloten JP, et al. J Immunother Cancer. 2022 Mar;10(3):e004335. doi: 10.1136/jitc-2021-004335. J Immunother Cancer. 2022. PMID: 35296558 Free PMC article.
AAV-Vectored Expression of the Vascular Normalizing Agents 3TSR and Fc3TSR, and the Anti-Angiogenic Bevacizumab Extends Survival in a Murine Model of End-Stage Epithelial Ovarian Carcinoma.
Stegelmeier AA, Santry LA, Guilleman MM, Matuszewska K, Minott JA, Yates JGE, Stevens BAY, Thomas SP, Vanderkamp S, Hanada K, Pei Y, Rghei AD, van Vloten JP, Pereira M, Thompson B, Major PP, Petrik JJ, Bridle BW, Wootton SK. Stegelmeier AA, et al. Among authors: van vloten jp. Biomedicines. 2022 Feb 2;10(2):362. doi: 10.3390/biomedicines10020362. Biomedicines. 2022. PMID: 35203573 Free PMC article.
Using a Prime-Boost Vaccination Strategy That Proved Effective for High Resolution Epitope Mapping to Characterize the Elusive Immunogenicity of Survivin.
Mould RC, van Vloten JP, AuYeung AWK, Walsh SR, de Jong J, Susta L, Mutsaers AJ, Petrik JJ, Wood GA, Wootton SK, Karimi K, Bridle BW. Mould RC, et al. Among authors: van vloten jp. Cancers (Basel). 2021 Dec 14;13(24):6270. doi: 10.3390/cancers13246270. Cancers (Basel). 2021. PMID: 34944889 Free PMC article.
23 results